- PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
- Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
- Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
- PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
- Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
- PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
- Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
- Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
- Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
More ▼
Key statistics
On Thursday, PAVmed Inc (PAVM:NAQ) closed at 2.14, 33.75% above the 52 week low of 1.60 set on Feb 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.61 |
---|---|
High | 2.66 |
Low | 2.14 |
Bid | 2.21 |
Offer | 2.27 |
Previous close | 2.73 |
Average volume | 88.09k |
---|---|
Shares outstanding | 9.17m |
Free float | 8.51m |
P/E (TTM) | -- |
Market cap | 19.63m USD |
EPS (TTM) | -9.24 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼